CONSULTING AGREEMENTConsulting Agreement • June 5th, 2024 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • Delaware
This CONSULTING Agreement (the “Agreement”) is entered into as of May 31, 2024 and is effective as of July 1, 2024 (the “Effective Date”), and is by and between Lixte Biotechnology Holdings, Inc., a Delaware corporation, having its principal place of business located at 680 East Colorado Boulevard, Suite 180, Pasadena, California 91101 (the “Company”), and Jan H.M. Schellens (the “Consultant”), an individual residing at Laag Nieuwkoop 10, 3628 GC Kockengen, The Netherlands.
